ENDV Endonovo Therapeutics Inc (PK)

Item 8.01 Other Events.

On April 10, 2020, the Registrant board of directors determined that, in light of the circumstances and uncertainty surrounding the effects of the COVID-19 pandemic on the business, consultants and service providers, that it will delay the filing of its annual report on Form 10-K for the year ended December 31, 2019 (the “Annual Report”) by up to 45 days in accordance with the SEC’s March 4, 2020 Order (Release No. 34-88318) (the “Order”), which allows for the delay of certain filings required under the Securities and Exchange Act of 1934, as amended. The Registrant’s operations and business have experienced disruption due to the unprecedented conditions surrounding the COVID-19 pandemic spreading throughout the United States and the world and thus the Registrant’s business operations have been disrupted and it is unable to timely prepare and review the Registrant’s financial statements for the 2019 fiscal year. As such, the Registrant will be making use of the 45-day grace period provided by the SEC’s Order to delay filing of its Annual Report. The Registrant plans to file its Annual Report by no later than May 14, 2020, 45 days after the original due date of its Annual Report. The Registrant is not able to predict with certainty the impact of the COVID-19 pandemic on its operations and results.